Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Search Results

A total of 248 matching records were found.

A075
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk- Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin’s Lymphoma

A085
A Pilot Trial of AVD in addition to Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma

A087
Protocol AMC-087: Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons with HIV Infection

ACRIN6685
ACRIN 6685: A Multicenter trial of FDG-PET/CT staging of head and neck cancer and its impact on the N0 neck surgical treatment in head and neck cancer patients

E1208
E1208 A Phase III Randomized, Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion

E1305
E1305 A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer

E1808
E1808 A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features

E2108
E2108 A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer

E2511
E2511 Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer

E2607
E2607 A Phase II Trial of Dasatinib in Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Solar Melanomas

E2905
E2905 Randomized Ph III Trial Comparing Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low or Intermediate-1 Risk MDS and Symptomatic Anemia

ECALGB90601
C90601 A Randomized double-blinded Phase III study comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin,and Placebo in patients with advanced Transitional Cell Carcinoma

ENSABPB43
B43 A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

ENSABPB47
B47 A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

ES1001
S1001 A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)

ES1007
S1007 Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial RX for Positive Node, Endocrine Responsive Breast Cancer

ES1216
S1216 A Phase III Randomized Trial Comparing Androgen Deprivation Therapy TAK-700 With Androgen Deprivation Therapy Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

G0264
G0264 A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary

G0277
G0277 A Phase III Randomized Trial of Gemcitabine plus Docetaxel Followed by Doxorubicin versus Observation for Uterus-Limited High-Grade Uterine Leiomyosarcoma (IRCI 001)

G9923
G9923 A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination with Continuous or Intermittent ABT-888 and Bevacizumab in Newly Diagnosed Patients with Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

J05121
A randomized phase II trial of Interferon GM-CSF versus K562/GM-CSF vaccination in CML patients achieving a complete cytogenetic response to frontline tyrosine kinase therapy

J0625
K562/GM-CSF Vaccination in Combination with Imatinib Mesylate as Booster for Chronic Myeloid Leukemia Patients Previously Vaccinated on Protocol J0345

J0647
Psychopharmacology of psilocybin in cancer patients

J0650
Multicenter Selective Lymphadenectomy Trial II: A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node

J0656
A Phase I efficacy and safety study of HPV16-specific therapeutic DNA-Vaccinia vaccination in combination with topical imiquimod, in patients with HPV16 high grade cervical dysplasia (CIN2/3)

J0676
A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients with Sickle Cell Anemia and Other Hemoglobinopathies

J0703
A Phase I/II Study of 131I-Tositumomab in Patients with Relapsed/Refractory Hodgkin�??s Lymphoma

J0739
Treatment of Patients with Hepatic Neuroendocrine Metastases using Drug-Eluting Bead Embolization

J0810
A randomized three-arm, neoadjuvant and adjuvant, feasibility and toxicity study of a GM-CSF secreting allogeneic pancreatic cancer vaccine administered either alone, or in combination with either a single intravenous dose, or daily metronomic oral doses of cyclophosphamide for the treatment of patients with surgically resected adenocarcinoma of the pancreas

J08106
DEFIBROTIDE FOR PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE (VOD): A TREATMENT IND STUDY (UNDER CFR 312.34)

J08126
A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Cross-Over, Phase II.5 Study of AZD0530, a Selective Src Kinase Inhibitor, In Patients with Recurrent Osteosarcoma Localized to the Lung

J08130
Cytokine Expression During Radiation Therapy for Breast Cancer

J0841
Phase I/II study of high dose interleukin 2, aldesleukin, in combination with the histone deacetylase inhibitor entinostat in patients with metastatic renal cell carcinoma.

J0866
A Pilot Study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)

J0867
Exploration and estimation of intratumoral concentration and activity of lapatinib in vivo in vestibular schwannomas.

J09111
Imaging of Viral Thymidine Kinase Activity in EBV-Associated and KSHV-Associated Malignancies

J09121
A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men with Castration Resistant Prostate Cancer

J09143
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL, POETIC and ITCC T2008-002

J0947
J0947, A Randomized, Open-Label Comparative Study of Combination Therapy with Cyclophosphamide and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine With or Without Trastuzumab for the Treatment of Metastatic Breast Cancer that Does NOT Over-express HER-2/neu

J0964
Pancreaticoduodenectomy With or Without Braun Enteroenterostomy: Comparison of Postoperative Pancreatic Fistula and Delayed Gastric Emptying.

J0988
A Phase II Study of Treatment De-Intensification in Favorable Squamous Cell Carcinoma of the Oropharynx

J1013
J1013: A Phase II Study of Gemcitabine and nab-Paclitaxel in Combination with GDC-0449 (Hedgehog Inhibitor) in Patients with Previously Untreated Metastatic Adenocarcionoma of the Pancreas

J10130
A Phase 2 Study of Paclitaxel with Cisplatin vs Fluoropyrimidine with a Platinum Agent for NeoadjuvantTherapy in Operable Esophageal Cancer Based on CHFR Methylation Status in Diagnostic Biopsies

J10140
Patient-donor vaccination in the context of allogeneic BMT incorporating high-dose posttransplantation cyclophosphamide

J1051
A Phase 1 Study of the PARP Inhibitor ABT-888 in Combination with Temozolomide in Acute Leukemias.

J1055
Reduced intensity, partially HLA mismatched allogeneic BMT for hematologic malignancies using donors other than first-degree relatives

J1060
Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With Neutropenia

J1071
Intra-arterial chemotherapy for the treatment of intraocular retinoblastoma

J1097
A Phase I Study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies with peritoneal carcinomatosis with two additional dose levels in patients with epithelial ovarian, fallopian or primary peritoneal cancers and intra-abdominal disease.

J11102
A Phase I trial of oral 5-azacitidine in combination with romidepsin in advanced solid tumors, with an expansion cohort in non-small cell lung cancer

J11105
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients with, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction

J11106
A Multi-arm Phase I Safety Study of Nivolumab in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects with Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC).

J11107
PHASE 2, multi-center, single arm investigation of HSPPC-96 vaccine with temozolomide in patients with newly diagnosed Glioblastoma Multiforme

J11110
A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects with BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer (M12-895)

J11114
A Multicenter Access and Distribution Protocol for unlicensed cryopreserved Cord Blood Units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications

J11116
A Pilot Study of Sorafenib in Patients with Acute Myeloid Leukemia as Peri-Transplant Remission Maintenance

J11120
A phase II trial of low dose fractionated radiation therapy as a chemo-potentiator of salvage temozolomide for recurrent anaplastic astrocytoma and glioblastoma multiforme

J11136
A Phase 1 Study of BMS-936558 Plus Sunitinib or Pazopanib in Subjects with Metastatic Renal Cell Carcinoma (CA209-016)

J1115
Administration of an Allogeneic Myeloma GM-CSF Vaccine in Conjunction with a Lenalidomide Containing Regimen in Myeloma Patients with Near Complete Remission.

J11155
Pre-Operative PARPi and Irradiation (POPI) in Women with an Incomplete Response to Neo-Adjuvant Chemotherapy for Breast Cancer

J11157
Stereotactic Body Radiation Therapy and Short-Term Androgen Ablation for Intermediate-Risk, Localized, Adenocarcinoma of the Prostate

J11159
A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies (BMT CTN 1101)

J11164
Intra-arterial chemotherapy for the treatment of progressive diffuse intrinsic pontine gliomas (DIPG).

J11165
A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, versus Placebo with Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer

J1124
A Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-small cell lung cancer.

J1130
J1130, Phase 1b/2 Safety and Feasibility of Gemcitabine and Nab-Paclitaxel in combination with LDE-225 as Neoadjuvant Therapy in Patients with Borderline Resectable Pancreatic Adenocarcinoma.

J1137
An Early Phase 1 Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors

J1141
Genome Wide Admixture for Multiple Myeloma in Africian Americans. (Africian-American MM GWAS)

J1151
Shortened-duration tacrolimus following nonmyeloablative, related donor BMT with high-dose posttransplantation cyclophosphamide

J1152
Allogeneic Hematopoietic Cell Transplant for Hematologic Cancers and Myelodysplastic Syndrome in HIV-Infected Individuals

J1161
Phase I/II study of safety and efficacy of Muscadine Plus (MPX) in men with prostate cancer: A randomized, double-blind, placebo-controlled study of the effects of two doses of MPX capsule on rising prostate-specific antigen in men following initial therapy for prostate cancer

J1162
A phase I study determining the safety and tolerability of combination therapy with Pazopanib, a VEGFR/PDGFR/Raf inhibitor, and GSK1120212, a MEK inhibitor, in advanced solid tumors enriched with patients with advanced differentiated thyroid cancer, soft tissue sarcoma, and cholangiocarcinoma.

J1164
A Randomized Controlled Study of YONDELIS (Trabectedin) or Darcarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma

J1179
Pilot Study Evaluating An Allogeneic GM-CSF-Transduced Pancreatic Tumor Cell Vaccine (GVAX) and Low Dose Cyclophosphamide Integrated with Fractionated Stereotactic Body Radiation Therapy (SBRT) and FOLFIRINOX chemotherapy in Patients with Resected Adenocarcinoma of the Pancreas

J1188
A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Previously Untreated Advanced/Metastatic Pulmonary Adenocarcinoma

J1191
Evaluation of PSMA-based PET as an imaging biomarker of primary prostate cancer

J1192
A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer

J1194
Phase I study of Mebendazole in Newly Diagnosed High-Grade gliomas

J1203
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study To Evaluate The Efficacy And Safety Of Afatinib (BIBW 2992) As Adjuvant Therapy After Chemo-Radiotherapy In Primary Unresected Patients With Stage III, IVa, Or IVb Loco-Regionally Advanced Head And Neck Squamous Cell Carcinoma.

J1209
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy

J1210
A Phase III Clinical Trial Evaluating TheraSphere in Patients with Metastatic Colorectal Carcinoma of the Liver who have Failed First Line Chemotherapy (EPOCH)

J12102
J12102:An Exploratory Study of the Biologic Effects of Nivolumab(BMS-936558/CA209-038 (Anti-PD1 Monoclonal Antibody) Treatment in Subjects with Advanced Melanoma (Unresectable or Metastatic)

J12106
A phase II trial of partially HLA-mismatched (HLA-haploidentical) bone marrow transplantation for high-risk solid tumors.

J12108
A Randomized Open Label Phase II Study Of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone In The Treatment Of Patients With Persistent Or Relapsed Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma

J12111
A Phase 2 Study of the mTOR Inhibitor Everolimus in Combination with Bevacizumab in Patients with Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors

J12114
Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to less than 18 Years with Advanced BRAF V600-Mutation Positive Solid Tumors

J12115
Lipiodol as an imaging biomarker of tumor necrosis after transcatheter chemoembolization therapy in patients with primary and metastatic liver cancer

J12121
A Phase I, open-label, dose escalation study of oral LGK974 in patients with malignancies dependent on Wnt ligands

J12127
A Phase II Trial of Hippocampal-Sparing Prophylactic Cranial Irradiation (PCI) for Small Cell Lung Cancer (SCLC)

J12128
A RANDOMIZED STUDY EVALUATING THE EFFECT OF A REMOTE-BASED WEIGHT LOSS PROGRAM (POWER-REMOTE) ON BIOMARKERS IN WOMEN WITH EARLY STAGE BREAST CANCER

J12129
IMAGE Study: Individualized Molecular Analyses Guide Efforts in Breast Cancer – Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins

J12131
A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects with NUT Midline Carcinoma (NMC) and Other Cancers (BET115521)

J12133
Phase II Study of Post-Operative Stereotactic Radiosurgery for Solid Tumor Spine Metastases

J12137
Single-Arm Phase II Study of Stereotactic Body Radiation Therapy Concurrent with Nelfinavir for Oligometastases

J12138
J12138, A Phase II trial to improve outcomes in patients with resected pancreatic adenocarcinoma at high risk for recurrence using epigenetic therapy

J1214
J1214, A multi-institutional open label, trial evaluating the efficacy of Gemcitabine and Docetaxel in patients with relapsed or refractory metastatic colorectal adenocarcinoma with methylated CHFR and/or microsatellite instability phenotype

J1217
A Multicenter Phase 2 Study of the Bruton’s Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma

J1220
J1220: A Phase I/II Pharmacodynamic Study of Hydroxychloroquine in Combination with Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer.

J1224
Phase II Trial of Molecularly Determined Treatment of Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

J1227
Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior

J1228
A Trial of maintenance Rituximab with mTor inhibition after High-dose Consolidative Therapy in CD20+, B-cell Lymphomas, Gray Zone Lymphoma, and Hodgkin’s Lymphoma

J1229
A Phase 1B/2 Study to Evaluate the Safety and Efficacy of PF-04449913, an Oral Hedgehog Inhibitor, in Combination with Intensive Chemotherapy, Low Dose ara-C or Decitabine in Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

J1231
T2009-003 A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL

J1232
Digoxin as a Novel Inhibitor of Global Hypoxia Inducible Factor-1a (HIF-1a) Expression & Downstream Targets in Breast Cancer: DIG-HIF1 Pharmacodynamic Trial

J1233
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination with Bendamustine/Rituximab (BR) in Subjects with Relapsed or Refractory Non-Hodgkin's Lymphoma

J1239
A Phase 1 Study of CSL362 (Anti-IL3Ra / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission with Incomplete Platelet Recovery at High Risk for Early Relapse

J1248
A Phase II Study Investigating CHFR Methylation Status As A Biomarker For Taxane Sensitivity Using Modified Docetaxel, Cisplatin and 5 Flourouracil In Patients With Metastatic Esophageal, Gastroesophageal And Gastric Cancer.

J1249
A Phase 1b/II Study of GDC-0068 or GDC-0980 with Abiraterone Acetate versus Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy (GO27983)

J1256
A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (Nivolumab, BMS 936558) and the Combination of Nivolumab and Ipilimumab in Subjects with Relapsed or Refractory Hematologic Malignancy

J1260
A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM

J1262
Understanding Mechanisms of Response and Resistance to Androgen-Directed Therapies in Men with Advanced Prostate Cancer Through Interrogation of Tumor Biopsies

J1264
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors.

J1265
A neoadjuvant immunologic study of androgen deprivation therapy combined with a GM-CSF–secreting allogeneic prostate cancer vaccine and low-dose cyclophosphamide in men with high-risk localized prostate cancer undergoing radical prostatectomy

J1266
A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy Followed By Standard Chemoradiation In HPV-Negative or High-risk HPV-Positive Locally Advanced Stage III/IVa/IVb HNSCC

J1269
J1269: A Phase I Trial of Dinaciclib (SCH727965) and MK2206 in Metastatic Pancreatic Cancer with an Expansion Cohort in Advanced Pancreatic Cancer

J1271
J1271: A Randomized Three Arm Phase II Study of (1) Everolimus, (2)Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)

J1273
Phase II Study to Evaluate Stereotactic Body Radiation Therapy For Palliative Management of Unresectable Recurrent or Residual Pancreatic or Periampullary Adenocarcinoma

J1274
A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel with MORAb-004 in Metastatic Soft Tissue Sarcoma

J1276
A Phase 1 Study of Ipilimumab in relapsed and refractory high risk myelodysplastic syndrome and acute myeloid leukemia with minimal residual disease

J1281
J1281, A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

J1282
A Phase I Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

J1283
A Randomized, Open-label, Phase II, Multi-center Trial of Gemcitabine (G) with Pazopanib (P) or Gemcitabine (G) with Docetaxel (T) in Previously Treated Subjects with Advanced Soft Tissue Sarcoma

J1284
Pre-operative Paravertebral Blocks to Decrease Post-operative Pain Following Mastectomy with Immediate Tissue Expander Reconstruction

J1286
Long-Term Follow-Up Study of Patients who were Treated with Lethally-Irradiated GM-CSF–Transduced Allogeneic Prostate Cancer Cell Vaccine (Prostate GVAX)

J1289
Validation of Dose Estimation Methods and Measurement of Normal Liver Dose in Y-90 Therasphere Therapy with Quantitative Nuclear Imaging

J1292
A study to determine the sensitivity and specificity of plasma and cerebrospinal fluid exosome EGFRvIII detection compared to tissue EGFRvIII detection by qPCR assay of exosomal RNA.

J1299
A pilot study investigating antitumorigenic potential of topical itraconazole in the treatment of basal cell carcinoma

J1301
An open-label, randomized, Phase 2, parallel, dose-ranging, multicenter, study of sotatercept for the treatment of patients with anemia and low- or intermediate-1 risk myelodysplastic syndromes or non-proliferative chronic myelomonocytic leukemia (CMML)

J1303
Phase II Trial Of CAPOX+Bevacizumab+Trastuzumab For Patients With HER2-Positive Metastatic Esophagogastric Cancer.

J1304
Presenting Patient-Reported Outcomes Data to Improve Patient and Clinician Understanding and Use

J1307
A phase 2, randomized, 3-arm study of abiraterone acetate alone, abiraterone acetate plus degarelix, a GnRH antagonist, and degarelix alone for patients with prostate cancer with a rising PSA or a rising PSA and nodal disease following definitive radical prostatectomy (PCCTC LOI#c11-092)

J1308
A Randomized, Open-label, Phase 3 Trial of A AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

J1309
A Randomized Phase II Trial of Cytotoxic Chemotherapy with or without Epigenetic Priming in Patients with Advanced Non-Small Cell Lung Cancer.

J1310
A Phase I Dose Escalation Study of Cabazitaxel in Pediatric Patients with Refractory Solid Tumors including Tumors of the Central Nervous System

J13101
A Phase I Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

J13104
A Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with ER Negative Early Stage Breast Cancer (PBI 3.0)

J13105
Early Detection of Pancreatic Cystic Neoplasms

J13108
J13108 - A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab in Combination with Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer

J13109
A Phase II Study of Rindopepimut/GM-CSF in Patients with Relapsed EGFRvIII-Positive Glioblastoma (The “ReACT” Study)

J13111
A Phase II Randomized, Double-Blinded, Placebo-Controlled Study of Pracinostat in Combination with Azacitidine in Patients with Previously Untreated International Prognostic Scoring System (IPSS) Intermediate Risk 2 or High-Risk Myelodysplastic Syndrome (MDS)

J13119
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

J13121
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects with Advanced Malignancies (ORAX-01-13-US)

J13122
Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT

J13126
Prospective Randomized Clinical Feasibility Study of Red Cell Transfusion Goals in Patients with Acute Leukemias

J13127
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients with KRAS Mutant Non-Small Cell Lung.

J13128
A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy with Cytarabine, Daunorubicin and Etoposide (AcDVP16) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDS

J13129
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications

J13137
A Phase Ib Multi-Cohort Trial of MK-3475 in Subjects with Hematologic Malignancies

J13138
A Pilot Study of SGI-110 in Combination with an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC) as Maintenance Therapy

J13142
A Phase 2B, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS-207 Compared to Chemotherapy or to CRS-207 Alone in Adults with Previously-Treated Metastatic Pancreatic Adenocarcinoma

J13146
J13146: An Exploratory Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects with Metastatic Pancreatic Adenocarcinoma

J13147
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients with Platinum-Resistant Ovarian Cancer

J1315
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer (ARN-509-003)

J13150
Adjuvant axitinib treatment of renal cancer: A randomized double-blind Phase 3 study of adjuvant axitinib vs. placebo in subjects at high risk of recurrent RCC (Protocol: AP311736)

J13151
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients

J13152
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the treatment of Chronic Myelomonocytic Leukemia (CMML) and Cataloging the Molecular Consequences of JAK2 Inhibition in Chronic Myelomonocytic Leukemia: A Correlative Study

J13153
A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

J13161
A Pediatric Blood and Marrow Transplant Consortium (PBMTC) multi-center Phase II Pilot Trial of Myeloablative Conditioning and Transplantation of Partially HLA-mismatched T cell replete Bone Marrow with post-transplantation cyclophosphamide for Pediatric Patients with Hematologic Malignancies

J13165
A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who received no prior therapy for advanced disease

J13168
(CO-338-014) A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

J13174
A Pilot Trial of Nelfinavir for the Lytic Activation and Treatment of Gammaherpesvirus-Related Tumors

J13177
A Randomized, Double-Blind, Placebo-Controlled Study Of Chemotherapy Plus Cetuximab In Combination With VTX- 2337 In Patients With Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck.

J1318
A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

J1319
Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside (ara-C) with and without the Checkpoint Kinase 1 (CHK1) Inhibitor MK-8776 in Adults with Relapsed

J1320
J1320: A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined with nab-Paclitaxel Plus Gemcitabine Compared with nab-Paclitaxel Plus Gemcitabine in Subjects with Stage IV Previously Untreated Pancreatic Cancer

J1322
Combination of External Beam Radiotherapy with 153Sm-EDTMP to Treat High Risk Osteosarcoma

J1326
(MC1114) A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 with Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian tube Cancers

J1327
CLDE225C2301: A Phase II, multi-center, open-label, single-arm study of the efficacy and safety of oral LDE225 in patients with Hh pathway activated relapsed medulloblastoma

J1331
Optimized antiretroviral therapy during allogeneic hematopoietic stem cell transplantation in HIV-1-infected individuals

J1332
LCCC-1231: Observational Longitudinal Study of Pain in Men with Metastatic Castrate-Resistant Prostate Cancer

J1333
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy®) in Patients with Metastatic Melanoma

J1337
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects with Advanced Solid Tumors

J1343
A Randomized Phase II Study of Autologous Stem Cell Transplantation with Tadalafil and Lenalidomide Maintenance with or without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma

J1346
Phase II Trial of Dovitinib in BCG-Refractory Urothelial Carcinoma Patients with Tumor FGFR3 Mutations or Over-expression: Hoosier Oncology Group GU12-157

J1347
J1347: A Phase 1/2A Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults with Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy.

J1348
A Phase I Study of Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer

J1349
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting (NALA)

J1353
A Randomized Phase II Study of Epigenetic Priming with Azacitidine and Entinostat Prior to Nivolumab versus Nivolumab Alone in Subjects with Recurrent Metastatic Non-Small Cell Lung Cancer.

J1354
Pilot study of rituximab and brentuximab vedotin with deferred BMT for relapsed classical Hodgkin lymphoma

J1356
J1356: STEAM (Sequencing Triplet with Avastin and Maintenance): Folfoxiri/Bevacizumab Regimens (Concurrent and Sequential) Vs. Folfox/Bevacizumab in First-Line Metastatic Colorectal Cancer

J1357
A Pilot Study of Allopurinol as a Modifier of 6-MP Metabolism in Pediatric ALL

J1360
Chemoradiation OR Brachytherapy for RECTal cancer

J1363
A phase 1b study of the safety and tolerability of INCB039110 in combination with gemcitabine and nab-paclitaxel in subjects with advanced solid tumors

J1365
Phase 2 Study of MK-3475 in Patients with Microsatellite Unstable (MSI) Tumors

J1366
Role of Human Papillomavirus in Head and Neck Squamous Cell Cancer

J1367
A Phase II Study of Hypofractionated Stereotactic Radiotherapy in the Treatment of Metastatic Pediatric Sarcomas of Bony Sites

J1368
Bone Marrow Transplantation and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance

J1369
J1369, A phase I study of SGI-110 combined with irinotecan followed by a randomized phase II study of SGI-110 combined with irinotecan versus regorafenib in previously treated metastatic colorectal cancer patients

J1370
Evaluation of Tumor Motion Management Strategies in Radiotherapy Using 4D-MRI

J1376
A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma.

J1377
A Randomized Phase II Study of Adjuvant Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination with Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT Trial)

J1378
A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects with Malignant Pleural Mesothelioma.

J1382
A Pilot Study of Stereotactic Radiosurgery combined with Ipilimumab in Patients with Newly Diagnosed Melanoma Metastases in the Brain and Spine

J1383
A Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients with Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations.

J1390
A Phase Ib/II, Open-Label Study Of LJM716 In Combination With BYL719 Compared To Taxane Or Irinotecan In Patients With Previously Treated Esophageal Squamous Cell Carcinoma.

J1391
A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy (XL184-308)

J1394
Cancer of the Pancreas Screening-5 A multi-center clinical trial

J1395
A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (CO-338-017)

J1396
T2009-008: A Phase I Study of GNKG168 in Pediatric Patients with Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (IND#113600)

J1403
Pilot Study Assessing the Feasibility of a Surgery and Chemotherapy-Only Approach in the Upfront Therapy of Children with Wnt Positive Standard Risk Medulloblastoma

J1404
A Randomized Phase IIB Open Label Study of Nivolumab or Nivolumab in Combination with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM)

J1408
A Phase 2 Study of Bicalutamide Plus Finasteride in Men with MRI Detectable Prostate Nodules Undergoing Active Surveillance

J1412
Study of 99mTc-Sestamibi SPECT/CT Imaging for the Preoperative Diagnosis of Renal Oncocytoma

J1416
A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) followed by Enzalutamide or Abiraterone Post-BAT in Men with Prostate Cancer Progressing on Combined Androgen Ablative Therapies RE-sensitizing with Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

J1421
A Phase 1b, Open-Label, Multicenter Study of Urelumab (BMS-663513) in Combination with Cetuximab in Subjects with Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck

J1426
“A Randomized Phase II Study of Subventricular Zone (SVZ) Irradiation Plus Temozolomide in Newly Diagnosed Glioblastoma Multiforme”

J1429
A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults with NF1- Associated Morbid Plexiform Neurofibromas

J1432
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas

N1101
A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects with Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment

N1202
Phase I Study of AZD1775 (MK-1775) with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients with Recurrent Glioblastoma

NCTNA0577
N0577 Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma

NCTNE1Z11
E1Z11 A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

NCTNE2112
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer

NCTNE2810
E2810 Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy

NCTNE3311
E3311 Phase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

NCTNE4412
E4412 A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

NCTNIG3004
G3004 SOLO1 A Phase III, Randomized, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy (D0818C00001)

NCTNN0229O
G0229O A Randomized Phase II Study with a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination with GSK2141795, an AKT Inhibitor, in Patients with Recurrent or Persistent Endometrial Cancer

NCTNN0281
G0821 A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK1120212) in Patients with Recurrent or Progressive Low-grade Serous Ovarian Cancer or Primary Peritoneal Cancer

NCTNS1203
S1203 A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)

NCTNS1207
S1207 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu-Negative Breast Cancer

PAALL0434
Intensified Methotrexate, Nelarabine (Compound 506U78; IND# 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia

PAALL05B1
A Children?s Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens

PAALL0932
Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)

PAALL1131
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum

PAAML1031
A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD.

PACNS02B3
ACNS02B3 A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens

PACNS0334
A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children less than 36 Months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy without Methotrexate

PACNS0821
Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial

PACNS0831
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years

PACNS1123
Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)

PACNS1221
ACNS1221 A Phase II Study for the Treatment of Non-Metastatic NodularDesmoplastic Medulloblastoma in Children Less Than 4 Years of Age

PAEWS1031
A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma

PAHOD04B1
Hodgkin Disease (HD) Banking Study

PANBL0032
ANBL0032 Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue

PANBL1221
ANBL1221, A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma

PANBL12P1
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma

PANHL04B1
Rare and Cutaneous Non-Hodgkin Lymphoma Registry

PANHL1131
ANHL1131, Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma (NHL) or Mature B-cell Leukemia (B-AL): Evaluation of Rituximab Efficacy and Safety in High Risk Patients.

PAREN03B2
Renal Tumors Classification, Biology, and Banking Study

PASCT1221
A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children with Juvenile Myelomonocytic Leukemia (JMML)

PrE0102
PrE0102 Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Fulvestrant (Faslodex) plus Everolimus in Post-Menopausal Patients with Hormone-Receptor Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy

R0926
R0926 A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging

R0937
R0937 Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)

SUBENSABPB47
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer. NSABP B47

TBCRC022
A Phase II Trial of HKI-272 (Neratinib) and Capecitabine for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Metastases

TBCRC026
A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer

TBCRC030
A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with Triple Negative Breast Cancer without Germline BRCA Mutations: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker

 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer